Figure 2.

This figure illustrates the percentage of patients who achieved ≥1 CR at any time in each sparsentan dose cohort that they were assigned to during the OLE. The percentage of patients shown is out of 100% at each dose level. The remaining percentage at each dose level represents the non-CR patients. The CR and non-CR groups did not differ in mean (454.1 vs. 406.8 mg/d, respectively) or median (399.8 vs. 399.9 mg/d, respectively) sparsentan dose. In the absence of randomization, descriptive analysis with no formal statistical testing was performed. CR, complete remission; OLE, open-label extension.